ERBB2 and non-small cell lung carcinoma: Suzawa et al[8] reported the antitumor effect of afatinib in vitro in NSCLC cells with ERBB2 mutation or amplification, suggesting that afatinib was a therapeutic option as a HER2-targeted therapy for NSCLC patient with ERBB2 alterations.